WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Protagonist Therapeutics earnings were $56.2M for the trailing 12 months ending Mar 31, 2025, with -66.3% growth year over year. The latest PTGX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$11.7M, down 108.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PTGX reported annual earnings of $275.2M, with -448.5% growth.

PTGX past earnings growth

How has PTGX's earnings growth performed historically?

Company
-66.29%
Industry
11.53%
Market
34%
PTGX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PTGX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PTGX earnings history

Current Revenue
$207.8M
Current Earnings
$56.2M
Current Profit Margin
27%

PTGX Return on Equity

Current Company
9.2%
Current Industry
-60.2%
Current Market
31.5%
PTGX's Return on Equity (9.2%)... subscribe to Premium to read more.
High Return on Equity Performance

PTGX undefined

Current Company
8.3%
Current Industry
-2.5%
PTGX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PTGX announces earnings.

PTGX undefined

Current Company
8.07%
Current Industry
5.8%
PTGX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PTGX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PTGX$59.97M$56.19M-66.29%$0.90
SWTX-$247.19M-$253.93MN/A-$3.41
RARE-$511.44M-$549.58MN/A-$5.87
SRPT-$109.09M-$248.39MN/A-$2.51
CRSP-$362.52M-$385.66MN/A-$4.50
View Top Biotech Stocks

Protagonist Therapeutics Earnings Reports & History FAQ

What were Protagonist Therapeutics's earnings last quarter?

On PTGX's earnings call on Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 2025 earnings per share (EPS) of -$0.19, up 105.57% year over year. Total PTGX earnings for the quarter were -$11.66 million. In the same quarter last year, Protagonist Therapeutics's earnings per share (EPS) was $3.41.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

Is Protagonist Therapeutics profitable or losing money?

As of the last Protagonist Therapeutics earnings report, Protagonist Therapeutics is currently profitable. Protagonist Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $56.19 million, a 65.34% decrease year over year.

What was PTGX's earnings growth in the past year?

As of Protagonist Therapeutics's earnings date in Invalid Date, Protagonist Therapeutics's earnings has grown -66.29% year over year. This is 77.82 percentage points lower than the US Biotechnology industry earnings growth rate of 11.53%. PTGX earnings in the past year totalled $56.19 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.